Full-Time

Project Manager R&D NPI Medical Devices

m/f/d

Novanta

Novanta

1,001-5,000 employees

Provides core photonics for medical tech

No salary listed

Berlin, Germany

In Person

Willingness to travel up to 20% globally (Czech Republic, US).

Bachelor's, MBA

Category
Business & Strategy (1)
Required Skills
Agile
Risk Management

Get referred to Novanta

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Engineering, Business, or related field
  • 5+ years of experience managing complex, technical projects, preferably in medical device or similar regulated industries
  • Proven ability to lead cross-functional teams and deliver results in a matrixed environment
  • Strong proficiency in project management tools and methodologies (Agile, Waterfall, PMP)
  • Excellent communication, problem-solving, and stakeholder management skills
  • Willingness to travel globally (Czech Republic, US) periodically. Up to 20%
Responsibilities
  • Lead the end-to-end execution of large-scale projects for product development (NPI), ensuring adherence to scope, schedule, and budget across all development phases
  • Create and monitor project plans including milestone timelines, COGS, project costs, and NREs
  • Guide the project team through the individual development phases in compliance with Novanta’s Design Control Process
  • Align and coordinate shared resources within a global organization
  • Facilitate cross-functional collaboration through structured sprint planning, Obeya style meetings, and milestone fidelity reviews
  • Manage risk mitigation strategies, including resource planning, cost reduction opportunities, and contingency actions for technical challenges
  • Drive project financial tracking through cost forecasting, variance analysis, and alignment with program-level targets
  • Coordinate with OEM customers and internal stakeholders to ensure products are developed in compliance with regulatory and quality standards
  • Support continuous improvement initiatives by leveraging PMP tools, Kaizen methodologies, and agile workflows
  • Provide clear and consistent communication to leadership and team members, ensuring transparency and accountability
  • Implementation of departmental and product group strategy
  • Coordination with other project managers on processes, interfaces and cross-functional tasks
  • Active participation in the innovation process & continuous improvement
  • Strict compliance with quality, occupational safety and environmental regulations.
Desired Qualifications
  • PMP certification and/or MBA are a plus

Novanta designs and supplies core technology platforms for precision photonics used in medical devices and advanced industrial equipment. Its products are components and subsystems—such as lasers, optics, sensors, and imaging hardware—that OEMs integrate into their own machines. Unlike companies that sell end-user devices, Novanta focuses on providing the underlying photonics technology that OEMs build into products, enabling reliable performance and scalable manufacturing. The company differentiates itself through deep specialization in photonics and by growing through acquisitions, aligning its portfolio toward medical technology and precision industrial markets. Its goal is steady, long‑term growth by delivering proven core technologies that help customers develop better medical devices and industrial solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bedford, Texas

Founded

1968

Get referred to Novanta

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 Q2 revenue hit $265.8 million, and management raised 2026 guidance.
  • Riverpoint closed July 27, 2026, doubling recurring medical consumables to roughly $300 million.
  • June 9, 2026 private placement raised $300 million, funding acquisitions and capacity moves.

What critics are saying

  • Novanta paid $1.2 billion for Riverpoint, then owes a $250 million milestone in Q1 2027.
  • July 2026 plant moves in Syracuse and Mukilteo show execution strain and job cuts.
  • If Riverpoint integration misses, Novanta’s premium medical pivot and margin story break fast.

What makes Novanta unique

  • Novanta’s June 2026 Riverpoint deal deepens proprietary minimally invasive surgical consumables with OEM control.
  • Novanta sells core subsystems, not full machines, embedding inside medical and industrial OEM designs.
  • Novanta’s precision manufacturing, robotics, and surgery portfolio supports sticky, recurring customer relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company News

Informa TechTarget
Aug 18th, 2026
Experts call FCC's block on foreign robotics a nearshoring tactic.

Experts call FCC's block on foreign robotics a nearshoring tactic. While cyberthreats are a growing risk to national security, the agency's sweeping block on humanoids, quadrupeds and mobile robot imports could reinvigorate domestic suppliers. Published Aug. 18, 2026 First published on Following the Trump administration's move last month to block the sale of advanced industrial robots from all countries outside of the United States, experts are mixed on the outcome but ultimately supportive of what this could mean from a supply standpoint. The Federal Communications Commission on July 28 updated its covered list to include imports of mobile robots, such as humanoids and quadrupeds, as well as connected power inverters, citing national security risks. Products meeting those definitions can no longer receive FCC equipment authorization and cannot be imported, marketed or sold in the U.S., making them essentially banned. Affected companies can apply for a conditional approval. The sweeping action, which immediately took effect, came amid growing concern over China's ability to surveil customers and obtain sensitive data around the world from devices assembled in the country. However, it also looks to address another issue entirely - the U.S. falling behind globally in terms of robot production and deployment. "Domestically, we need help," Robert Little, a business development advisor and former chief of robotics strategy at Novanta, said. At first glance, Little said he thought the move was necessary for cybersecurity reasons. But after looking at the FCC's similar action regarding drones and drone parts, he said the recent ban was also a mechanism to drive domestic production of humanoids and mobile robots, as well as incentive for foreign suppliers to build their supply chains in the U.S. "That's its ultimate purpose," Little said. "And I think it can be effective." The U.S. is considered one of the global robotics leaders when it comes to investor capital, fueled by surging interest in AI, foundation model research and robotics systems. U.S.-headquartered companies such as Figure AI, Agility Robotics and Tesla received 52% of the $9.4 billion in global venture capital deployed last year, according to the Robotics Center of Silicon Valley. However, there is a widening gap between the number of robots manufactured by U.S. companies versus Chinese competitors. China installed 295,000 robots in 2024, representing more than half of the world's market share, according to the International Federation of Robotics. While preliminary 2025 numbers have not been released yet for China, the group estimated that installations are about ten times higher than the U.S. In other words, the "U.S. leads the world in where robotics is heading...while losing the race on where robotics is shipping today," the Robotics Center of Silicon Valley said in its 2026 report. To address the issue, the Association for Advancing Automation has urged Congress to consider adopting a national robotics strategy that includes subsidies, tax incentives and other means to drive domestic adoption and production of U.S. robots. The FCC's move, which only applies to new products, creates a runway for domestic companies to become more competitive, Little said. Then if the restrictions are lifted in the next few years, "they'll be in a much better place." Erik Nieves, founder and CEO of Plus One Robotics, said he knew the Trump administration would put restrictions on China's robots but was surprised by the breadth of the FCC's ban. Rather than just targeting China, the move affected robotics from all other countries, including trade partners such as Japan, Germany and South Korea. "We would have preferred to see it be more circumspect, but you don't control what the government does," Nieves said. "If it's true that every action is an overreaction, that's what this is." He also pointed out that the impact of the ban depends on the complexity of the conditional approval from the U.S. Department of Defense. Nieves said the details are unclear about the exemption process, adding that if it's more than just a simple check, then the U.S. could be "excessively hampering partners that we really would not rather do that to." Some say the ban doesn't go far enough. In a recent LinkedIn post, Standard Bots CEO Evan Beard said that fixed industrial robot arms should be part of the FCC's covered list because, similar to mobile robots, they have a networked, sensing, actuated system and raise security risks.

Yahoo Finance
Aug 14th, 2026
Novanta beats Q2 estimates, raises full-year revenue guidance to $1.14B

Novanta reported second-quarter revenue of $265.8 million, beating analyst estimates of $262.3 million with 10.3% year-on-year growth. The medical technology company also exceeded expectations on adjusted earnings per share ($0.89 versus $0.83 estimated) and adjusted EBITDA ($60.73 million versus $58.88 million estimated). CEO Matthijs Glastra attributed the performance to organic growth across all business units, driven by increased demand in precision robotics, AI-driven manufacturing, and minimally invasive surgery. New product revenue jumped more than 50% year-on-year. The company raised its full-year revenue guidance to $1.14 billion at the midpoint from $1.05 billion, an 8.4% increase. Management also lifted adjusted earnings guidance to $3.71 per share at the midpoint. During the earnings call, analysts questioned humanoid robotics deployments, Gen AI data centre exposure, and core gross margin evolution.

Yahoo Finance
Aug 7th, 2026
Novanta raises outlook to $1.14B revenue after Riverpoint acquisition doubles medical consumables to $300M

Novanta reported strong second-quarter results with 9% organic sales growth, 16% adjusted EBITDA increase, and 17% adjusted earnings per share growth. Adjusted gross margin expanded to 47%, whilst operating cash flow reached $65 million, bringing year-to-date cash flow to $117 million. The Automation Enabling Technologies segment led growth with 12% higher revenue and 18% bookings increase. Generative AI-related applications represented approximately 17% of revenue and grew roughly 25%. The company also received its first major servo-drive orders for humanoid robot development. Following the Riverpoint Medical acquisition closure, Novanta raised its 2026 outlook. The company now expects revenue of $1.13 billion–$1.14 billion, adjusted EBITDA of $273 million–$278 million, and adjusted EPS of $3.68–$3.74.

Yahoo Finance
Aug 5th, 2026
Novanta's Q2 sales beat estimates at $266M, lifts full-year revenue guidance to $1.14B

Novanta, a medicine and manufacturing technology provider, reported second-quarter revenue of $265.8 million, beating analyst estimates of $262.3 million and marking 10.3% year-on-year growth. The company's non-GAAP earnings of $0.89 per share exceeded expectations by 7.2%. Novanta raised its full-year revenue guidance to $1.14 billion at the midpoint, up from $1.05 billion—an 8.4% increase. The company also lifted its full-year adjusted EPS guidance to $3.71 and EBITDA guidance to $275.5 million, above analyst estimates of $247.3 million. Next quarter's revenue guidance of $302 million came in 14.9% above analyst expectations. Free cash flow margin improved to 21.6% from 4.8% in the same quarter last year, though operating margin declined to 6.8% from 11.4%.

Yahoo Finance
Aug 5th, 2026
Novanta reports $266M Q2 2026 revenue with 10% growth and adjusted EBITDA up 16% to $61M

Novanta announced its financial results for the second quarter of 2026, reporting GAAP revenue of $266 million, a 10% increase year-over-year. The medical and advanced technology equipment manufacturer achieved organic revenue growth of 9%, marking its strongest quarter since the first quarter of 2023. GAAP net income reached $13 million, whilst adjusted EBITDA rose 16% to $61 million. GAAP diluted earnings per share stood at $0.30, compared to $0.12 in the prior year. Adjusted diluted EPS increased 17% to $0.89. Chair and CEO Matthijs Glastra highlighted the company's performance, noting it exceeded expectations across revenue, margins, and profitability, with an adjusted EBITDA margin of 23%.